title: The p85 regulatory subunit of PI3K mediates TSH-cAMP-PKA growth and survival signals.
abstract: Phosphatidylinositol 3-kinase (PI3K) is necessary for thyroid stimulating hormone (TSH)-induced cell cycle progression. To determine the molecular mechanism linking PI3K to TSH, we have identified a serine residue in p85alpha(PI3K) phosphorylated by protein kinase A (PKA) in vitro and in vivo. Expression of an alanine mutant (p85A) abolished cyclic AMP/TSH-induced cell cycle progression and was lethal in thyroid cells (FRTL-5). The aspartic version of the p85alpha(PI3K) (p85D) inhibited apoptosis following TSH withdrawal. The p85alpha(PI3K) wild type not the p85A bound PKA regulatory subunit RIIbeta in cells stimulated with cAMP or TSH. The binding of the aspartic version of p85alpha(PI3K) to RIIbeta was independent of cAMP or TSH stimulation. Similarly, binding of PI3K to p21Ras and activation of AKT, a downstream PI3K target, were severely impaired in cells expressing the p85A mutant. Finally, we found that the catalytic activity of PI3K was stimulated by TSH in cells expressing the wild-type p85alpha(PI3K) but not in cells expressing p85A. This latter mutant did not affect the epidermal growth factor-stimulated PI3K activity. We suggest that (1) TSH-cAMP-induced PKA phosphorylates p85alpha(PI3K) at serine 83, (2) phosphorylated p85alpha(PI3K) binds RIIbeta-PKA and targets PKAII to the membrane, and (3) PI3K activity and p21Ras binding to PI3K increase and activate PI3K downstream targets. This pathway is essential for the transmission of TSH-cAMP growth signals.
authors.affiliation: Dipartimento di Patologia Molecolare IRCCS Neuromed, Località Camerelle, Pozzilli, Italy.
authors.forename: G
authors.initials: G
authors.lastname: De Gregorio
authors.forename: A
authors.initials: A
authors.lastname: Coppa
authors.forename: C
authors.initials: C
authors.lastname: Cosentino
authors.forename: S
authors.initials: S
authors.lastname: Ucci
authors.forename: S
authors.initials: S
authors.lastname: Messina
authors.forename: A
authors.initials: A
authors.lastname: Nicolussi
authors.forename: S
authors.initials: S
authors.lastname: D'Inzeo
authors.forename: A
authors.initials: A
authors.lastname: Di Pardo
authors.forename: E V
authors.initials: EV
authors.lastname: Avvedimento
authors.forename: A
authors.initials: A
authors.lastname: Porcellini
mesh_terms: D000818:Animals; D002384:Catalysis; D002453:Cell Cycle / Q000235:genetics; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival; D002478:Cells, Cultured; D000242:Cyclic AMP / Q000378:metabolism*; D054757:Cyclic AMP-Dependent Protein Kinase RIIbeta Subunit; D017868:Cyclic AMP-Dependent Protein Kinases / Q000378:metabolism*; D051379:Mice; D009154:Mutation; D019869:Phosphatidylinositol 3-Kinases / Q000235:genetics / Q000378:metabolism*; D010766:Phosphorylation; D021122:Protein Subunits / Q000235:genetics / Q000378:metabolism; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism; D016283:Proto-Oncogene Proteins p21(ras) / Q000378:metabolism; D051381:Rats; D012694:Serine / Q000235:genetics / Q000378:metabolism; D013972:Thyrotropin / Q000378:metabolism* / Q000494:pharmacology
chemical_list: D054757:Cyclic AMP-Dependent Protein Kinase RIIbeta Subunit; C517838:Prkar2b protein, mouse; C517839:Prkar2b protein, rat; D021122:Protein Subunits; D012694:Serine; D013972:Thyrotropin; D000242:Cyclic AMP; D019869:Phosphatidylinositol 3-Kinases; D051057:Proto-Oncogene Proteins c-akt; D017868:Cyclic AMP-Dependent Protein Kinases; D016283:Proto-Oncogene Proteins p21(ras)